{"name":"Cidara Therapeutics","slug":"cidara","ticker":"CDTX","exchange":"NASDAQ","domain":"cidara.com","description":"Cidara Therapeutics is a biopharmaceutical company focused on developing novel anti-infectives and antifungals. The company's lead product candidate, rezafungin, is a novel echinocandin antifungal agent being developed for the treatment of invasive fungal infections. Cidara Therapeutics has a strong pipeline of product candidates targeting various infectious diseases. The company is well-positioned to capitalize on the growing demand for effective treatments against infectious diseases.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"Jeffrey Stein","sector":"Anti-Infectives / Antifungals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":42000000,"revenueGrowth":-98,"grossMargin":0,"rdSpend":71879000,"netIncome":-169827000,"cash":214796000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"Rezafungin patent cliff ($0.0B at risk)","drug":"Rezafungin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CD101","genericName":"CD101","slug":"cd101","indication":"Treatment of invasive fungal disease","status":"phase_2"}]}],"pipeline":[{"name":"CD101","genericName":"CD101","slug":"cd101","phase":"phase_2","mechanism":"CD101 is a recombinant human monoclonal antibody targeting beta-glucan.","indications":["Treatment of invasive fungal disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Cidara Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Cidara Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline and strong cash position.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Cidara Therapeutics Announces Collaboration with the Bill and Melinda Gates Foundation to Develop Rezafungin for the Treatment of Invasive Fungal Infections in Low- and Middle-Income Countries","summary":"Cidara Therapeutics announced a collaboration with the Bill and Melinda Gates Foundation to develop rezafungin for the treatment of invasive fungal infections in low- and middle-income countries.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Cidara Therapeutics Announces Positive Topline Results from Phase 3 Clinical Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis","summary":"Cidara Therapeutics announced positive topline results from its Phase 3 clinical trial of rezafungin for the treatment of candidemia and invasive candidiasis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNeU1RM1lRVW9tcDR6S2lJcGxhZ0ZRUW0tYy1qYTV0aTJHeDh0S2hFMm9vOXJnOGxBTkdaelA2a1dUVDBSRkFqVTVEUThpNXZ2OF9WLXFoRHRPU1RaaFo0bVBkYjlXTldWOU9NRXdibDEzTmhTRHEzTW1MSmtyd3JqNTgtNk54Qm1Db3ZsaWtndmVwZWFiOW1N?oc=5","date":"2025-11-20","type":"pipeline","source":"The Motley Fool","summary":"Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. - The Motley Fool","headline":"Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPd2trX2ZUME1VcHNYajh3M0ktQUR0S1F5V2oySkd3eXlub0piVDd6Z256azFXRkJvQWlyWnNaekk0eGN6TXhQVnFWdkZ1SFYwZXhTUGc3ek1XNjF3Ty14Q1B6TS1SMndXOHJKNU5Kanc0VkZTalRiOE5VVkY0RjNVaW1OdXZDUG5saVFvWEZGQ3puTFdCLTRhS1RaRlJIUHhVcU1XNjFHMExLcE9vOThuTDAzem45amRDSXlpMjlEOThjcjJjNUticndnZTZOUmNzT0RweUQwNA?oc=5","date":"2025-11-17","type":"pipeline","source":"reuters.com","summary":"Merck sees over $5 billion opportunity in Cidara's experimental flu drug - reuters.com","headline":"Merck sees over $5 billion opportunity in Cidara's experimental flu drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1MN0Rna00wMjJObVJKZzZmUk5sVm4wRUJUdXZpV2MzaGViS3JaaG0xUXJBUjdKb2gxZzN5MzdjQTdpMDBCc2pXWUdTalJUSFNpMkt4MXRPdE5IQlRvb2ZsN2Q1WW1ubmJ4czdweXdtQ04xVDQ?oc=5","date":"2025-11-17","type":"deal","source":"Yahoo Finance","summary":"MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026 - Yahoo Finance","headline":"MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQdUw1YUkyNHJ1YkpnT2dSX0RLRHRWMG1QSmJiOW9FUEtNU1NmYksxWm5uZU8zeXRGbzZSenUySDREc09iZ2FHaExIYjZyU2lLbi1GOGtITUJZSVhtYVZEWG1QX3pTSFlvcTVQdkoybzJwbG0tMDlGdlg5akRvNV9CblBOZkNYWldDUUxMYndSSkFEdHVhb09CZ0R3bkJqNFp0NXR4eUdOUGNydw?oc=5","date":"2025-11-15","type":"pipeline","source":"Finviz","summary":"Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid - Finviz","headline":"Cidara Therapeutics (CDTX) Skyrockets 105% on Merck $9.2-Billion Acquisition Bid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE1HemZETzExNjhQazVrZXY1RGFrVUEwbEw4QnhMMWRUdmMxNjBGNzRFQUtsR3hVQks2dmdNZVlCcTJ2Wm53VFdKcHJybFJQYWpBTlMyalphLW11SUowMW5URGxiYmk2Mzg1R3VXQXBHVXBUd1BvYXo0cmo4NTlCQdIBgwFBVV95cUxOdjV1YnlXTXNJNFZvRjRWWlJZbnRHZjdUZUJrckJYb1N6X1lQeEh0WjhUMnpjX0VfWERCT1ZxZXpWMTBYbEtwbFk1cFhyS1BIcUtaWHZsVFU0ZVhlUFJCV3cyakF0RmYxemRrZGxsRzR1aEdPUG9vZ1ZDUmRJd0plekI0QQ?oc=5","date":"2025-11-14","type":"deal","source":"CNBC","summary":"Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics - CNBC","headline":"Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxObFN3aGxGM2JVMWRLZ0w5cnQtY29MeVV2Q1lyLXFJTjJyZ3liZFM2U0RSWkNwV2V3TUU1dldpQ0tIY1d0UlVuNkZiZXpvSUw0aWdkY05hUWwzU0xFLW1SV3dDTWwtcEh4SC1FUW4tNXBmcEJ4ODRXNDVtaEdoOTRRSUNueEZGRllzM2Z6ZC10NE9NZEMyaXBTajBuSkY?oc=5","date":"2025-11-14","type":"deal","source":"The Pharma Letter","summary":"Merck to buy Cidara Therapeutics in $9.2 billion deal - The Pharma Letter","headline":"Merck to buy Cidara Therapeutics in $9.2 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQWTBJM04zcXNIWE1scWRKdElIZm5tUlJxWmhWcm8zSTlQbTNaSzlGSVdCb3FBSDVXN21IQ0Q4cXFDb3dlRU1EWm1fYTQxUkZHSnk5LTN5WThyR1JLcXlSTGpKU3NXMXBpTlRzVGt6TkVoWEc5ZEhqdWJUa0VYNG1iWjZNMTYzTGhVVTc3ZzlUSjQ0ekRZMmttcg?oc=5","date":"2025-11-14","type":"regulatory","source":"CNBC","summary":"Stocks making big premarket moves: WBD, CDTX, AVDL and more - CNBC","headline":"Stocks making big premarket moves: WBD, CDTX, AVDL and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPWGtSak13bFFkVmpKTUJWRjVUNjVYMVRaVzdTbHV6NGk0WnpadjFCRFdVSGwyRG1EWlkyNGJ2RU9idExmVExOWE52YVBrd3FoRXFEUkNVN2ZEWEFNelNNWE9hMkhfR3hwVHZ6dXZsczVEXzZPRzlNbTZvTUk0Q2ljWDluWExSRVV2YjlyZENZaXNFRDZMQV9pSU1hT3BDVGViNWw4M3ladFFfV29lWlVtbmliRW83WkJ3dEFleGRJRGlkU1NOSUN0MU9SWHREZXJQZ3lRNHI0cWIyQlk2OF9ZbjgtRk13T3RvV1RuUzY0enhWaGRBUkE?oc=5","date":"2025-11-14","type":"pipeline","source":"Benzinga","summary":"Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Benzinga","headline":"Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPcm9qTXFtSkZsVjBBSzRVYzllaGxLVk00UDBneFRFcUZhMVYzaXBRLXVqWVVKMTNWMGdkODZpRU5xVXFvUDJUS1hueEw4WGk4MUl2alFnLXRxcUhFejJERTBVVWEwejh6RkN3dkcwS29kenYtcW9xVTNtM0toalYxUlRlR0JBYkN1WXR3dmhpYkZ6OXhVdEtNd0ZsUlBfdjdVWHEyTFdCNEVQZ1NXby1LXw?oc=5","date":"2025-11-14","type":"deal","source":"Seeking Alpha","summary":"Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why (NASDAQ:CDTX) - Seeking Alpha","headline":"Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why (NASDAQ:CDTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNczdlYTJ2bm1IMDY3eXZvRlpodjJhenNUbmRmcWZOaFd6ZWYya0R3U1VEUFF0bmZ3VDFCZ3ZCbkhscE8tRWxmVEt2d2swNUx5ZjFDS2FlT1FLTE9NQlFCRnc2eEpEbGp3Wk1icG9XYVJvaG9aUUY4WUM2bmlBaW5hRWptSjhlSVdxZzV6VzJUOC1mQ3c1Y1llaG1weThHZG5oS2hUZktEcXFhN1VpbWw0Q1N2N0JoZUFqWFFoX2JnWXlENHFoZk9xYk4zcFpUa2FkcEZoRzVacHJRN3lETlNpRGJMLTZkMkdQTmRvb0lLbm1aOUJQd3c?oc=5","date":"2025-11-14","type":"trial","source":"Business Wire","summary":"Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent - Business Wire","headline":"Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxObkVfWmZUYldrTXpZWmxsend2aXhXNWFHUDdnLUhnMUlBV1lLNHQ0ZEt1RVpqOHJJeHJpYVZrRGpDQ2JCRW9NbG1USmZNWU9sTlhXRF9RVndEb05JNnV1Um5QWFVJYklmei1CTVZ5Z3lLTzF2LVFBY1QtTHIxYlpQNG1qdHNGR0VydjRia25HX3ZFaGMwYWw0T1RWT3pSODJXUzN4bWlBNE5iTjJn?oc=5","date":"2025-11-13","type":"deal","source":"reuters.com","summary":"Merck nearing deal for Cidara, FT reports - reuters.com","headline":"Merck nearing deal for Cidara, FT reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxObTUzSnlyRFAxSTltRy16WnR1aVBZVmhCWkRGVTVScEZNSjllWmNERkM1cW1qUlhsRldDWHpXajZDTVNpQ0JVTV9hWXY3cjItcVc3VDNHTXVzRkZiVjZpbVR2SGQwSjlHQnpzbDFsZ3NpNGd0aHQ5elNyWjFQcnZfQ1ZrT0ZIbjdQVHdyQUhTWGdoOFBjM3lBQVZNSHhvUTUtUjJVRDhNVE5ydWpBcWpPU0U5TXVYcllsVEdkMQ?oc=5","date":"2025-08-15","type":"trial","source":"Seeking Alpha","summary":"Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX) - Seeking Alpha","headline":"Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout (CDTX)","sentiment":"neutral"}],"patents":[{"drugName":"Rezafungin","drugSlug":"rezafungin","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co., Inc.","Pfizer Inc.","Gilead Sciences, Inc."],"therapeuticFocus":["Anti-Infectives / Antifungals"],"financials":{"source":"sec_edgar+yahoo","revenue":1275000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":1275000,"period":"2024-12-31"},{"value":63905000,"period":"2023-12-31"},{"value":23283000,"period":"2023-12-31"},{"value":46322000,"period":"2023-09-30"},{"value":12718000,"period":"2023-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":71879000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-169827000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":214796000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}